15 completed, 13 unknown, 10 recruiting, 6 terminated. 19 Phase 2, 18 Phase 1, 7 Not applicable, 2 Early Phase 1, 2 Phase 3.
Follow Pyloric Stenosis, Hypertrophic: new trials by email Literature Review of Pyloric Stenosis, Hypertrophic trials Research Report on Pyloric Stenosis, Hypertrophic
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Axatilimab + CAR-T for High-Risk Lymphoma Axatilimab - Diffuse Large B Cell Lymphoma (DLBCL), Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma | Phase 1 | Not yet recruiting | Northside Hospital, Inc. | 29 | 2026-12-31 | 2026-10-16 |
| Imaging Study of [89Zr]DFO-YS5 for Cancer Detection [89Zr]DFO-YS5, Positron Emission Tomography (PET)-Computerized tomography (CT) - Bladder Cancer, Nerve Sheath Tumor | Phase 1 | Recruiting | Robert Flavell, MD, PhD | 40 | 2026-06-15 | 2026-10-01 |
| Testing an Enhanced Digital Delivery Model for Inherited Cancer Genetic Testing in Young Adults With Cancer Telemedicine, Genetic Testing, Internet-Based Intervention - Miscellaneous Neoplasm, Nos, Non-Neoplastic Condition, Nos | Not applicable | Recruiting | Alliance for Clinical Trials in Oncology | 535 | 2025-12-10 | 2026-10-02 |
| Existential Distress in Advanced Cancer: Comparing a Short-term Psychodynamic Psychotherapy (ORPHYS) to Treatment as Usual (TAU) ORPHYS (ShORt-term psychodynamic psychotherapy in serious PHYSical illness), TAU (Treatment As Usual: Standard psycho-oncological care) - Advanced Cancer, Various, NOS | Not applicable | Recruiting | Universitätsklinikum Hamburg-Eppendorf | 160 | 2025-10-24 | 2025-12-31 |
| Pilot Study of IT Topotecan and Maintenance Chemotherapy for HR-EBTs in Children < 6 Years, Post Consolidation Cytarabine IT, hydrocortisone, Cisplatin - CNS Embryonal Tumor, CNS, Medulloblastoma | Early Phase 1 | Recruiting | C17 Council | 15 | 2025-09-23 | 2026-07-14 |
| Brentuximab Vedotin Combined With R-CHP in Newly Diagnosed EBV+ DLBCL-NOS BV+R-CHP - EBV-Positive Diffuse Large B-Cell Lymphoma, Nos, Brentuximab Vedotin | Phase 2 | Not yet recruiting | The First Affiliated Hospital with Nanjing Medical University | 25 | 2025-09-01 | 2025-09-30 |
| Venetoclax + Azacytidine for Newly Diagnosed ETP-like ALL and T-ALL With Myeloid Mutations Venetoclax, Azacitidine, Cytarabine - Early T Acute Lymphoblastic Leukemia, T-Acute Lymphoblastic Leukemia | Phase 2 | Recruiting | yuejun Liu | 32 | 2025-04-01 | 2025-06-10 |
| Clinical Study of C402-CD19-CAR Treatment in Subjects With Relapsed or Refractory B-cell Lymphoma C402-CD19-CAR - Diffuse Large B-cell-lymphoma, DLBCL, Nos Genetic Subtypes | Phase 1 | Recruiting | Shanghai Exuma Biotechnology Ltd. | 18 | 2025-03-25 | 2026-09-11 |
| Embryonal Tumor With Multilayered Rosettes Radiotherapy (RT), Chemotherapy Drug, Cancer - Physician's Choice, Non-Investigational Surgical Resection - Embryonal Tumor With Multilayered Rosettes, Embryonal Tumor With Multilayered Rosettes, Nos | Phase 2 | Recruiting | University of California, San Francisco | 70 | 2025-03-06 | 2026-06-29 |
| SynKIR-310 for Relapsed/Refractory B-NHL SynKIR-310 - B Cell Lymphoma, NHL, Adult | Phase 1 | Recruiting | Verismo Therapeutics | 36 | 2024-11-01 | 2026-04-14 |
| Study of SGR-1505 in Mature B-Cell Neoplasms SGR-1505 - Mature B-Cell Neoplasm, Non Hodgkin Lymphoma | Phase 1 | Recruiting | Schrödinger, Inc. | 98 | 2023-04-10 | 2026-02-13 |
| Acalabrutinib + Liso-Cel In R/R Aggressive B-Cell Lymphomas ACALABRUTINIB, LISOCABTAGENE MARALEUCEL, Lymphodepleting chemotherapy - Refractory Aggressive B-cell Lymphomas, Refractory B-Cell Non-Hodgkin Lymphoma | Phase 2 | Active not recruiting | Patrick C. Johnson, MD | 28 | 2023-03-01 | 2026-01-29 |
| Selinexor in Combination With R-CHOP Followed by Selinexor Maintenance for Untreated EBV-positive DLBCL Patients Selinexor, R-CHOP Protocol - EBV-Positive Diffuse Large B-Cell Lymphoma, Nos | Phase 1 / Phase 2 | Unknown | Sun Yat-sen University | 54 | 2022-11-01 | 2023-12-14 |
| Phase 2 Study of Plamotamab Combined With Tafasitamab Plus Lenalidomide Versus Tafasitamab Plus Lenalidomide in Relapsed or Refractory (R/R) Diffuse Large-cell B-cell Lymphoma (DLBCL) Plamotamab, Tafasitamab, Lenalidomide - Diffuse Large-cell B-cell Lymphoma | Phase 2 | Terminated | Xencor, Inc. | 3 | 2022-04-15 | 2024-04-30 |
| Gastric Tube in Pyloric Stenosis Hypertrophic Pyloric Stenosis, Respiratory Complication | Completed | Centre Hospitalier Universitaire, Amiens | 87 | 2021-09-20 | 2026-06-12 | |
| An Open-Label Phase 2 Trial of Nanatinostat Plus Valganciclovir in Patients With EBV+ Relapsed/Refractory Lymphomas Nanatinostat in combination with valganciclovir - Epstein-Barr Virus Associated Lymphoma, EBV-Positive DLBCL, NOS | Phase 2 | Terminated | Viracta Therapeutics, Inc. | 102 | 2021-05-28 | 2025-07-28 |
| Tislelizumab in Combination With Lenalidomide in Refractory and Relapsed Elderly Patients With Non-GCB DLBCL PD-1 Antibody, Lenalidomide - Non-GCB/ABC Diffuse Large B-Cell Lymphoma, High-grade B-cell Lymphoma | Phase 1 / Phase 2 | Unknown | Huiqiang Huang | 30 | 2021-03-31 | 2021-03-15 |
| Iomab-ACT: A Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma 131-I Apamistamab, CAR T-cell - B-ALL, DLBCL | Early Phase 1 | Recruiting | Memorial Sloan Kettering Cancer Center | 12 | 2021-02-02 | 2026-02-17 |
| Zanubrutinib Combined With Tislelizumab in the Treatment of r/r PMBCL and EBV+ DLBCL Zanubrutinib, Tislelizumab - Primary Mediastinal Large B Cell Lymphoma, EBV-Positive DLBCL, Nos | Phase 2 | Unknown | Ruijin Hospital | 40 | 2021-01-01 | 2021-03-30 |
| A Study of TAS1553 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia (AML) and Other Myeloid Neoplasms TAS1553 - Acute Myeloid Leukemia, Myeloproliferative Neoplasm | Phase 1 | Terminated | Astex Pharmaceuticals, Inc. | 20 | 2020-12-21 | 2024-08-02 |
Showing 20 of 49. Sign in to see all of them.
Lymphoma, Large B-Cell, Diffuse (8) · Lymphoma, Follicular (5) · Lymphoma, B-Cell (4) · Lymphoma, B-Cell, Marginal Zone (3) · Lymphoma, Mantle-Cell (3) · Lymphoma, Non-Hodgkin (3) · Neuroectodermal Tumors, Primitive (3) · Recurrence (3) · Waldenstrom Macroglobulinemia (3) · Astrocytoma (2) · Burkitt Lymphoma (2) · Dendritic Cell Sarcoma, Interdigitating (2) · Glioblastoma (2) · Glioma (2)
Digestive System Diseases (49) · Gastric Outlet Obstruction (49) · Stomach Diseases (49) · Gastrointestinal Diseases (48) · Pyloric Stenosis (48) · Neoplasms by Histologic Type (19) · Neoplasms (18) · Immune System Diseases (15) · Hemic and Lymphatic Diseases (13) · Immunoproliferative Disorders (12) · Lymphatic Diseases (12) · Lymphoproliferative Disorders (12) · Lymphoma (11) · Pathologic Processes (10) · Pathological Conditions, Signs and Symptoms (10)
Cyclophosphamide (5) · Lenalidomide (4) · Vincristine (4) · Doxorubicin (3) · Rituximab (3) · Filgrastim (2) · Granulocyte Colony-Stimulating Factor (2) · Prednisolone (2) · R-CHOP protocol (2) · Temozolomide (2) · tislelizumab (2) · 4-(5-(cyclopropylcarbamoyl)-2-methylphenylamino)-5-methyl-N-propylpyrrolo(1,2-f)(1,2,4)triazine-6-carboxamide (1) · Anesthesia, General (1) · Anesthesia, Spinal (1) · Azacitidine (1)
Bristol-Myers Squibb (4) · Huiqiang Huang (3) · The First Affiliated Hospital with Nanjing Medical University (3) · Alliance for Clinical Trials in Oncology (2) · Memorial Sloan Kettering Cancer Center (2) · Xencor, Inc. (2) · Astex Pharmaceuticals, Inc. (1) · BiO2 Medical (1) · Bnai Zion Medical Center (1) · C17 Council (1) · Centre Hospitalier Universitaire, Amiens (1) · Children's Mercy Hospital Kansas City (1) · Copenhagen University Hospital, Rigshospitalet (1) · Dr Caeymaex Laurence (1) · Drugs for Neglected Diseases (1)
United States (23) · China (11) · France (8) · Canada (7) · Italy (5) · Spain (5) · Germany (3) · South Korea (3) · United Kingdom (3) · Australia (2) · Denmark (2) · Taiwan (2) · Argentina (1) · Brazil (1) · Czechia (1)
Wei Xu, M.D., Ph.D. (2) · Alan Ho, MD (1) · Angela Bradbury, MD (1) · Annie Huang (1) · Chet Bohac, PharmD, MD, MSc (1) · Connor Johnson, MD (1) · Daniel J Ostlie, MD (1) · Darrel P Cohen, MD, PhD (1) · Derek Hanson, MD (1) · Dr. Peter Metrakos, MD (1) · Frank G Basile, M.D. (1) · Gary A Levy, MD FRCP AGAF (1) · Giles W. Robinson, MD (1) · Harold L Atkins, MD FRCP(C) (1)
PMID 28153605, PMID 28478586, PMID 28576557, PMID 28793993, PMID 29722835, PMID 30480549, PMID 31744509, PMID 32756081, PMID 33422612, PMID 34049362, PMID 35065786, PMID 35398840, PMID 35867947, PMID 36918264, PMID 37325351, PMID 37530631, PMID 38182653, PMID 38218194, PMID 38636983, PMID 42098804
2009 (1), 2016 (1), UM1CA081457 (1)